Lilly agrees to settle 18,000 more Zyprexa cases

Share this article:
Eli Lilly agreed to pay up to $500 million to settle claims from about 18,000 patients who said the company hid the risks of weight gain and diabetes associated with Zyprexa. The cases had been set for trial in April. Lilly did not disclose terms of the settlement but said the amount was “substantially less” than the $700 million paid for more than 8,000 similar claims in a June 2005 settlement. Including those earlier settlements, Lilly has now agreed to pay at least $1.2 billion to people who said they were hurt by the antipsychotic drug. At least 1,200 suits are still pending, the company said. Lilly faces lawsuits from several states, and more states could sue. “While we remain confident that these claims are without merit…we wanted to reduce significant uncertainties involved in litigating such complex cases,” said Sidney Taurel, Lilly chief executive officer, in a statement. With sales of $4.2 billion in 2005, Zyprexa is Lilly’s top seller. The FDA in 2003 added a warning to antipsychotic drugs including Zyprexa about their tendency to cause high blood sugar. The federal judge supervising the Zyprexa litigation recently said that the 2003 label change makes future cases by Zyprexa patients “less viable, on statute of limitations grounds,” Lilly said. The agreement follows a review of documents in The New York Times last month that show Lilly played down the risks of Zyprexa to doctors and that it encouraged off-label use. Lilly has denied any wrongdoing and said it provided all relevant information to doctors and regulators. The company has also said it did not promote Zyprexa for conditions other than schizophrenia or bipolar disorder.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...